Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis

Shao-Jie Gao, Dan-Yang Li, Dai-Qiang Liu, Jia Sun, Long-Qing Zhang, Jia-Yi Wu, Fan-He Song, Ya-Qun Zhou, and Wei Mei

Abstract
Osteoarthritis (OA), a chronic degenerative disease, leads to pain and loss of function. Existing treatments for OA pain have limited efficacy and show significant side effects. Dimethyl fumarate, a robust nuclear factor erythroid 2-related factor 2 (Nrf2) activator, could alleviate pain behaviors in chronic pain. This study aims to investigate the role of dimethyl fumarate in a rat model of OA induced by monosodium iodoacetate (MIA) and its underlying mechanisms. We used von Frey filaments to assess the mechanical allodynia. Weight-bearing apparatus was employed to assess the hindlimb weight distribution. Western blot was employed to investigate the protein expressions of mitochondrial biogenesis markers. RT-qPCR was employed to examine the copy number of mitochondrial DNA (mtDNA). In our study, dimethyl fumarate upregulated mechanical paw withdrawal threshold (MPWT) (MIA + Vehicle, 1.6 ± 0.13 g [mean ± SEM]; MIA + Dimethyl fumarate (DMF) 300 mg/kg, 10.5 ± 0.96 g; p < 0.0001). Hindlimb weight distribution was also upregulated by dimethyl fumarate (MIA + Vehicle, 38.17 ± 0.72 g; MIA + DMF 300 mg/kg, 43.59 ± 1.01 g; p < 0.01). Besides, activation of Nrf2 remarkably upregulated the protein levels of PGC-1α (MIA + Vehicle, 0.69 ± 0.07; MIA + DMF 300 mg/kg, 1.08 ± 0.09; p = 0.0037), NRF1 (MIA + Vehicle, 0.69 ± 0.04; MIA + DMF 300 mg/kg, 1.00 ± 0.11; p = 0.0114), TFAM (MIA + Vehicle, 0.62 ± 0.11; MIA + DMF 300 mg/kg, 1.02 ± 0.12; p = 0.0147), and the copy number of mtDNA (MIA + Vehicle, 0.52 ± 0.05; MIA + DMF 300 mg/kg, 3.81 ± 0.21; p < 0.0001). Taken together, these results show that dimethyl fumarate alleviated pain-related behaviors in a rat model of OA through activation of Nrf2-induced mitochondrial biogenesis.

Keywords
Dimethyl fumarate, osteoarthritis pain, Nrf2, mitochondrial biogenesis

Introduction
Osteoarthritis (OA), one of the most disabling musculoskeletal conditions, is a huge burden to the social economy and affects the patient’s quality of life.1 Pain is a remarkable symptom of OA.2 The type of OA pain is still up for debate. Nerve damage, inflammatory, and damaged joint tissues might be the causes of OA pain.3–6 According to European League Against Rheumatism (EULAR) guidelines, pharmacologic treatment of OA pain relies primarily on NSAIDs and opioids.2 NSAIDs are insufficient to alleviate pain in OA, and opioids can produce significant adverse effects including nausea, dizziness, somnolence, respiratory depression, and vomiting. Therefore, an attractive therapeutic target needs to be further studied. Reactive oxygen species (ROS) are implicated in chronic pain development through several mechanisms, including oxidative stress and mitochondrial biogenesis impairment.7–11 Our previous study has shown that ROS scavengers could alleviate cancer-induced bone pain.8

Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Corresponding Author:
Ya-Qun Zhou and Wei Mei, Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Emails: yqzhou2019@hust.edu.cn, wmei@hust.edu.cn
Mitochondria participate in many physiological processes, such as energy production, calcium homeostasis, and cell death. Mitochondrial biogenesis is defined as the process of generating mitochondrial DNA (mtDNA), mitochondrial proteins, and new mitochondria.12 Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) regulates this process by promoting the expression of nuclear respiratory factors 1 and 2 (NRF1, NRF2) and mitochondrial transcription factor A (TFAM).13 Restoring mitochondrial biogenesis attenuated pain behaviors in a rat model of OA, paclitaxel-induced neuropathic pain, and SNI-induced neuropathic pain.14–16 Therefore, it is plausible that restoring mitochondrial biogenesis and redox balance might attenuate pain behaviors.

Nrf2 is involved in antioxidant defense as the main regulator.17,18 Although present studies have shown that Nrf2 activators have analgesic effects, the potential mechanisms remain elusive.19 For this reason, we have focused on Nrf2. Under normal circumstances, Nrf2 binds to Kelch-like ECH associated-protein 1 (Keap1) to form a complex, and then this complex is ubiquitinated for degradation. When oxidative stress occurs, Nrf2 is dissociated from Keap1 and translocated to the nucleus. When Nrf2 enters the nucleus, it binds to the antioxidant response elements to initiate the transcription of antioxidant-related genes.20 Recent evidence has indicated that Nrf2 promotes mitochondrial biogenesis via regulating PGC-1α.21 Moreover, our recent study has shown that RTA-408, an Nrf2 inducer, alleviated neuropathic pain via restoring mitochondrial biogenesis.22 Thus, Nrf2 is a promising therapeutic target to restore mitochondrial biogenesis.

Dimethyl fumarate (DMF), a potent Nrf2 activator, is favored by FDA of the United States to treat relapsing-remitting multiple sclerosis.23 It has been shown that DMF plays a vital role in neurological disease that could activate Nrf2 and produce a neuroprotection effect.24,25 Besides, DMF alleviated migraine induced by nitroglycerin in mice.26 Moreover, in a mouse model of spared nerve injury, DMF could markedly alleviate pain behaviors in neuropathic pain.27 Additionally, several lines of evidence have demonstrated that in other diseases, DMF restored mitochondrial biogenesis by activating Nrf2.28,29 Thus, our present study investigated that dimethyl fumarate, attenuated pain behaviors in OA rats through restoring mitochondrial biogenesis.

Materials and methods

Animals

SPF-rated adult male SD rats starting weight of 200–220 g supplied from the Experimental Animal Center of Tongji Hospital (Wuhan, China) were applied. These animals were kept in a SPF-rated facility that have 12 h of light and have free access to food and water. All animals’ experiments were approved by the ethics committee of the Animal Care and Use Committee of Tongji hospital of Huazhong University of Science and Technology. In the present study, animals were randomly grouped by randomization tools (https://www.random.org/lists/), and behavior tests were sequentially performed on each group of animals.

Establishment of the MIA-induced OA model and behavioral tests

A solution of monosodium iodoacetate (MIA; Sigma-Aldrich, USA) was prepared with saline solution. Mother liquor concentration was 20 mg/mL and it was stored at −80°C. Rats were first anesthetized with 2.5% sevoflurane and intraarticularly administrated MIA (1 mg/50 μL) on day 0 to induce OA.14 The control group was intraarticularly injected with the same volume of sterile saline solution (0.9%). After injection, animals were placed on a pre-prepared far-infrared warming pad in order to keep their body temperature between 35°C and 37°C until they woke up and we put them back into their cage. These animals didn’t receive postoperative analgesia after surgery which was avoided confounding the results of subsequent experiments.

Pain-related behavior tests including mechanical paw withdrawal threshold (MPWT) and weight-bearing asymmetry were experienced. As described earlier,20 we used von Frey filaments (Stoelting, Wood Dale, IL, USA) to examine MPWT. Firstly, rats were acclimated in plexiglass boxes for 30 min for 3 days in a row. Next, seven von Frey filaments from 1.4 g to 15 g, were employed to the left hind paw’s mid plantar area for 6s. The rat’s positive responses to hind paw stimulation consist of one or more elements as follows: (1) licking; (2) shaking; (3) sudden claw retraction. When one of the rat’s positive responses was observed more than three times, the reaction was considered positive. Otherwise, a stronger von Frey filament was applied until a positive reaction was observed. Based on our previous studies described,14 weight-bearing apparatus (TECHMAN, Chengdu, China) was used to assess the hindlimb weight distribution. Pain-related behaviors were experienced between 8:00 AM and 4:00 PM. All animals’ experiments were conducted blind to group assignment.

Drug administration

Dimethyl fumarate (DMF; Sigma-Aldrich, USA), a potent Nrf2 activator, was suspended in carboxymethylcellulose sodium (Solarbio, China) and administrated by oral gavage. The doses (30, 100, 300 mg/kg) of DMF used in this study were based on a previous study.27 An Nrf2 inhibitor, trigo-nelline hydrochloride (Sigma-Aldrich, USA), was dissolved with 0.9% saline solution and administrated by intraperitoneal injection. The experimental design protocol is described in Figure 1. To clarify if consecutive
administration of dimethyl fumarate, an Nrf2 activator, can attenuate established OA pain, dimethyl fumarate (30, 100, 300 mg/kg) was orally administered once a day from day 14 for 5 days in a row. All behavioral tests were experienced 2 hours after dimethyl fumarate administration every day. To clarify whether dimethyl fumarate can abolish the development of OA pain in the early stage of OA, starting from day 0, rats were orally administrated dimethyl fumarate (300 mg/kg) once a day for 7 days in a row. All behavioral tests were experienced on day 0 before the rat model was built, and on day 3, day 7, day 14, and day 21. To clarify if an Nrf2 inhibitor, trigonelline, can abolish the effect that dimethyl fumarate attenuate OA pain, 20 mg/kg trigonelline was intraperitoneal injection 30 min before dimethyl fumarate. All behavioral tests were experienced 30 min before inhibitor administration and 2 h after dimethyl fumarate administration.

**Western blotting**

When the rats were first anesthetized with 2.5% sevoflurane, the lumbar section of spinal cords was quickly removed, and placed in ice-cold mixture of radioimmunoprecipitation assay lysis buffer containing phosphatase inhibitor and phenylmethylsulfonyl fluoride (Boster; Wuhan, Hubei, China). The concentration of supernatants was examined by the Protein Assay Kit of Bicinchoninic Acid (BCA) (Boster). Then, the proteins were heated at 100°C for 15 min with loading buffer and stored at −80°C. The SDS PAGE (10%) was used to separate the samples, 30 μg protein, and then the samples

---

**Figure 1.** Schematic diagram of the experimental design. (A) Changes in pain-related behaviors after MIA injection in rats. (B) To clarify if consecutive administration of dimethyl fumarate, an Nrf2 activator, can attenuate established OA pain, dimethyl fumarate (30, 100, 300 mg/kg) was orally administered once a day from day 14 for 5 days in a row. All behavioral tests were experienced 2 hours after dimethyl fumarate administration every day. (C) To clarify whether dimethyl fumarate, can abolish the development of OA pain in the early stage of OA, starting from day 0, rats were orally administrated dimethyl fumarate (300 mg/kg) once a day for 7 days in a row. All behavioral tests were experienced on day 0 before the rat model was built, and on day 3, day 7, day 14, and day 21. (D) To clarify if an Nrf2 inhibitor, trigonelline, can abolish the effect that dimethyl fumarate attenuate OA pain, 20 mg/kg trigonelline was intraperitoneal injection 30 min before dimethyl fumarate. All behavioral tests were experienced 30 min before inhibitor administration and 2 h after dimethyl fumarate administration.
were transferred to 0.45 μm polyvinylidene fluoride membranes (PVDF; Millipore, USA). Next, the membranes were placed in 5% nonfat dry milk with 0.1% Tween-20 for 90 min at 24°C to block nonspecific binding sites. The membranes were placed in the following antibodies solution overnight at 4°C: rabbit anti β-actin antibody (1:200,000; rabbit monoclonal IgG; AC026; ABclonal), anti Nrf2 antibody (1:1000; rabbit polyclonal; AF7006; Affinity), anti PGC-1α antibody (1:3000; rabbit polyclonal; ab54481; Abcam), anti NRF1 antibody (1:4000; rabbit monoclonal; ab175932; Abcam), anti TFAM antibody (1:2000; rabbit monoclonal; ab252432; Abcam). The membranes were next washed for 15 min and placed in HRP-conjugated secondary antibody solution (1:5000; goat polyclonal; Aspen) for 1 h at 24°C. Lastly, the protein on membranes was visualized using the ECL Enhanced KIT (RM00021; ABclonal) and ChemiDoc XRS+ imaging system (Bio-Rad, CA, USA) were used to expose. Image Lab software system (Bio-Rad laboratories) were used to analyze the intensity of protein expression and the protein expressions of mitochondrial biogenesis markers were normalized to the protein expression of β-actin.

**Real-time polymerase chain reaction**

According to our past studies, we used the DNA extraction kit to extract mtDNA from the lumbar section of the spinal cord. qPCR was performed with SYBR Premix kit (EQ001, Wuhan, China). The level of mitochondrial gene ND1 (mtND1) was measured relative to the level of β-actin by the ΔΔCt method.

**Statistics**

All data are represented as means ± SEM. Prism version 8.0 (GraphPad) was used to analyze all data. The data from western blot and qPCR were tested by one-way ANOVA, followed by Bonferroni post hoc test. The behavioral data were tested by two-way ANOVA, followed by Bonferroni post hoc test. Statistical significance was defined as \( p < 0.05 \).

**Results**

**Intraarticular injection of MIA induced pain-related behaviors**

Firstly, we observed the mechanical allodynia between Vehicle rats and OA rats induced by MIA intraarticular injection. As shown in Figure 2(a), the ipsilateral MPWT of MIA-treated rats was significantly decreased beginning at day 3 and persisting till day 21 at least (**** \( p < 0.0001 \) vs. Vehicle group, \( n = 6 \) rats/group). Conversely, mechanical allodynia was not observed in vehicle group during the study period. As shown in Figure 2(b), weight-bearing asymmetry was remarkably decreased beginning at day 3 and persisting till day 21 at least (**** \( p < 0.0001 \) vs. Vehicle group, \( n = 6 \) rats/group). Based on these results, intraarticular injection of MIA (1 mg/rat) successfully induces pain-related behaviors in rats.

**Spinal mitochondrial biogenesis impairment in OA rats**

To clarify if mitochondrial biogenesis changes in OA rats, the protein expressions of mitochondrial biogenesis markers were examined in the lumbar section of the spinal cord. In comparison with Vehicle-treated rats, the protein expressions of mitochondrial biogenesis markers were remarkably downregulated in OA rats (Figure 3(a) to (c), * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \) vs. Vehicle group, \( n = 6 \) rats/group). Based on these results, mitochondrial biogenesis was markedly repaired in the rat model of OA.

**Expression of Nrf2 in the spinal cord of OA rats**

The protein expression of Nrf2 was measured by Western blotting. The protein expression of Nrf2 was remarkably decreased in OA rats from day 3 following MIA injection to day 21 (Figure 4(a), ** \( p < 0.01 \), *** \( p < 0.001 \) vs. Vehicle group, \( n = 6 \) rats/group).
This result indicates that the antioxidant defense system was impaired in OA rats. Analgesic effect of Nrf2 activator attenuated pain-related behaviors in a rat model OA

To clarify if dimethyl fumarate could alleviate pain behaviors in OA rats, dimethyl fumarate (30, 100, 300 mg/kg) was orally administrated once a day from day 14 for 5 days in a row. As illustrated in Figure 5(a), mechanical allodynia was markedly upregulated by repetitive oral administration of dimethyl fumarate (300 mg/kg) in MIA + DMF 300 mg/kg group (***p < 0.0001 vs. MIA + Vehicle group, n = 6 rats/group). Weight-bearing asymmetry was markedly reversed at day 18 (Figure 5(b) *p < 0.05 vs. MIA + Vehicle group, ****p < 0.0001 vs. Vehicle + Vehicle group, n = 6 rats/group). Compared with vehicle-treated rats, mechanical allodynia and weight-bearing asymmetry had no change in the 30 mg/kg and 100 mg/kg groups. These data indicate that pain-related behaviors were markedly alleviated by repetitive oral administration of dimethyl fumarate (300 mg/kg) in a rat model of OA.

To clarify if dimethyl fumarate could abolish pain behaviors in the early stage of OA pain development, 300 mg/kg dimethyl fumarate was orally administrated once a day for seven consecutive days from day 0. In comparison with vehicle group, the MPWT was markedly upregulated from day 3 for 5 days in a row in DMF-treated OA rats (Figure 5(c) and (d), ****p < 0.0001 vs. MIA + Vehicle group, n = 6 rats/group).

Figure 3. Spinal mitochondrial biogenesis impairment in OA rats. (A) After MIA administration, PGC-1α was remarkably downregulated in OA rats from day 7 to day 14 (**p < 0.01, ***p < 0.001 vs. Vehicle group, n = 6 rats/group). (B) After MIA administration, NRF1 was remarkably downregulated in OA rats from day 3 to day 21 (**p < 0.01, ****p < 0.0001 vs. Vehicle group, n = 6 rats/group). (C) TFAM was remarkably downregulated in OA rats from day 7 to day 21 after MIA injection (**p < 0.01, ***p < 0.001 vs. Vehicle group, n = 6 rats/group).

Figure 4. Expression of Nrf2 in the spinal cord of OA rats. (A) The protein level of Nrf2 was remarkably decreased in OA rats from day 3 after MIA injection to day 21 (**p < 0.01, ***p < 0.001 vs. Vehicle group, n = 6 rats/group).
Weight-bearing asymmetry was also upregulated on day 3 (\( p < 0.01 \) vs. MIA + Vehicle group, \( n = 6 \) rats/group). These data show that dimethyl fumarate delayed pain-related behaviors onset induced by MIA.

**Effect of Nrf2 activator on the spinal level of Nrf2 and spinal mitochondrial biogenesis**

To clarify whether the Nrf2 activator affected the protein expression of Nrf2 and impaired mitochondrial biogenesis in OA rats, 300 mg/kg dimethyl fumarate was orally administered once a day from day 14 for 5 days in a row. The protein expression of Nrf2 was remarkably upregulated after orally administrated dimethyl fumarate (Figure 6(a), \( **** p < 0.0001 \) vs. Vehicle + Vehicle group, \( n = 6 \) rats/group). The mtDNA copy number and the protein expressions of mitochondrial biogenesis markers were reversed by dimethyl fumarate treatment (Figure 6(b) to (e), \( * p < 0.05 \) vs. MIA + Vehicle group, \( n = 6 \) rats/group). Based on these results, dimethyl fumarate restored mitochondrial biogenesis in a rat model of OA and upregulated the expression of Nrf2.

**Reversal analgesic effect of Nrf2 inhibitor in OA rats**

To clarify whether trigonelline, an Nrf2 inhibitor, could abolish dimethyl fumarate’s analgesic effect, 20 mg/kg trigonelline was intraperitoneally administrated 30 min
before dimethyl fumarate. The behavioral tests were experienced before trigonelline administration and 2 h after dimethyl fumarate administration. As illustrated in Figure 7(a) and (b), the analgesic effect of dimethyl fumarate in OA rats was abolished by trigonelline (****p < 0.0001 vs. Vehicle + Vehicle group, n = 6 rats/group). These data show that dimethyl fumarate alleviated pain-related behaviors by activating Nrf2.

Reversal effect of trigonelline on the spinal level of Nrf2 and spinal mitochondrial biogenesis

To clarify if in OA rats, the Nrf2 inhibitor could reverse the effect of dimethyl fumarate on the protein level of Nrf2 and mitochondrial biogenesis, the protein expressions were examined by western blot. Figure 8(a) to (d) illustrated that the western blot data suggested that trigonelline remarkably reversed the effect that dimethyl fumarate affected mitochondrial biogenesis and the protein level of Nrf2 in a rat.
Discussion

Based on above results, we demonstrated that (1) mitochondrial dysfunction was involved in OA pain development; (2) the expression of Nrf2 was remarkably downregulated in OA rats; (3) dimethyl fumarate significantly alleviated pain behaviors and delayed the onset of pain behaviors in a rat model of OA; (4) dimethyl fumarate administration restored spinal mitochondrial biogenesis in OA rats; (5) the analgesic effect and mitochondrial biogenesis of dimethyl fumarate were reversed by trigonelline. Generally, these data show that dimethyl fumarate, an Nrf2 activator, alleviates pain behaviors in OA pain through activating Nrf2 and restoring mitochondrial biogenesis.

Consistent with our previous fundings, pain-related behaviors were rapidly onset and persisted until day 21 after injection of 1 mg of MIA. Interestingly, the duration of the nadir is different between MPWT and weight-bearing asymmetry. Unlike MPWT, which remained at its lowest point from day 3 to day 21, weight-bearing asymmetry rapidly decreased, reaching its lowest point on day 3, and then

---

**Figure 7.** Reversal analgesic effect of Nrf2 inhibitor in OA rats. (A) The MPWT was remarkably reversed from day 16 to day 18 (**p < 0.01, ****p < 0.0001 vs. MIA + Vehicle group, ##p < 0.01, ####p < 0.0001 vs. MIA + DMF 300 mg/kg + Tri 20 mg/kg group, n = 6 rats/group). (B) Weight-bearing asymmetry was reversed at day 18 (**p < 0.01 vs. MIA + Vehicle group, ###p < 0.001 vs. MIA + DMF 300 mg/kg + Tri 20 mg/kg group, n = 6 rats/group).
rose slightly. The underlying mechanisms may be that weight-bearing asymmetry is caused by central and peripheral sensitization whereas MPWT is caused by central sensitization.\textsuperscript{31–33} A limitation of our study was that only male rats were used and no female rats were used. A recent study has shown that in spared nerve injury mice, dimethyl fumarate produced no analgesic effect in mice lacking Nrf2, regardless of sex.\textsuperscript{27} Given the importance of sex differences in nociceptive hypersensitivity,\textsuperscript{34,35} this question will be investigated in further studies.

Oxidative stress is caused by the excessive production of ROS.\textsuperscript{36} Our previous study has shown that ROS scavengers could alleviate cancer-induced bone pain.\textsuperscript{8} Oxidative stress leads to mitochondrial dysfunction, in turn, mitochondrial

---

**Figure 8.** Reversal effect of trigonelline on the spinal level of Nrf2 and spinal mitochondrial biogenesis. (A) Trigonelline early treatment remarkably reversed the effect of dimethyl fumarate on the protein level of Nrf2 (****\(p < 0.0001\) vs. MIA + Vehicle group,####\(p < 0.0001\) vs. MIA + DMF 300 mg/kg + Tri 20 mg/kg group, \(n = 6\) rats/group). (B–D) Trigonelline early treatment remarkably reversed the effect of dimethyl fumarate on the protein levels of PGC-1\(\alpha\), NRF1, and TFAM (*\(p < 0.05\), **\(p < 0.01\), ****\(p < 0.0001\) vs. MIA + Vehicle group, #\(p < 0.05\), ##\(p < 0.01\), ###\(p < 0.001\), ####\(p < 0.0001\) vs. MIA + DMF 300 mg/kg + Tri 20 mg/kg group, \(n = 6\) rats/group).
dysfunction can produce more ROS. Our past studies have suggested that spinal mitochondrial biogenesis impairment was present in neuropathic pain. In this study, our results suggested that the mtDNA copy number was rapidly downregulated, as did the protein expressions of mitochondrial biogenesis markers. These data indicate that spinal mitochondrial biogenesis impairment was present in the rat model of OA.

Nrf2 plays a vital role in endogenous antioxidant defense. Our past studies have verified the importance of Nrf2 in chronic pain. In this study, we used western blot to examine the protein expression of Nrf2 in the spinal cord. The spinal protein expression of Nrf2 was significantly downregulated which indicated that the antioxidant system was impaired in the rat model of OA. However, this result was different from our previous study. One possible explanation is that the experiments used different animal models. This shows that Nrf2 might have distinctive effects in special animal models, which needs further investigation. This data was similar to past studies which demonstrated that Nrf2 was significantly decreased in the rat model of paclitaxel-induced neuropathic pain. Our behavioral tests indicated that re-dimethyl fumarate metabolism and produces monomethyl fumarate which might affect the development of pain in the brain. Future studies will be addressed this question.

In summary, our study indicates that Nrf2 activation significantly alleviated mechanical allodynia through restoring mitochondrial biogenesis in a rat model of OA. These data indicate that dimethyl fumarate may provide an effective therapy for restoring mitochondrial biogenesis and attenuating pain behaviors induced by MIA.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the National Natural Science Foundation of China (82071556, 81873793, 82001198, 82101310); and the National Key Research and Development Program of China (2020YFC2005303).

ORCID iD

Wei Mei  https://orcid.org/0000-0001-6556-6628

References

1. Briggs AM, Woolf AD, Dreinhofer K, Homb N, Hoy DG, Kopansky-Giles D, Akesson K, March L. Reducing the global burden of musculoskeletal conditions. Bull World Health Organ 2018; 96: 366–368. DOI: 10.2471/BLT.17.204891
2. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. The Lancet 2011; 377: 2115–2126. DOI: 10.1016/s0140-6736(11)60243-2
3. O’Neill TW, Felson DT. Mechanisms of osteoarthritis (OA) pain. Curr Osteoporos Rep 2018; 16: 611–616. DOI: 10.1007/s11914-018-0477-1
4. Krustev E, Rioux D, McDougall JJ. Mechanisms and mediators that drive arthritis pain. Curr Osteoporos Rep 2015; 13: 216–224. DOI: 10.1007/s11914-015-0275-y
5. Fu K, Robbins SR, McDougall JJ. Osteoarthritis: the genesis of pain. Rheumatology 2018; 57: iv43–iv50. DOI: 10.1093/rheumatology/kex419
6. Maffiari AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol 2013; 9: 654–664. DOI: 10.1038/nrrheum.2013.138
7. Trecarichi A, Flatters SJL. Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy. Int Rev Neurobiol 2019; 145: 83–126. DOI: 10.1016/bs.irn.2019.05.001
8. Zhou YQ, Liu DQ, Chen SP, Sun J, Zhou XR, Rittner H, Mei W, Tian YK, Zhang HX, Chen F, Ye DW. Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain. Redox Biol 2018; 14: 391–397. DOI: 10.1016/j.redox.2017.10.011
9. Zhou YQ, Liu DQ, Chen SP, Chen N, Sun J, Wang XM, Li DY, Tian YK, Ye DW. PPARgamma activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway. Biomed Pharmacother 2020; 129: 110356. DOI: 10.1016/j.biopha.2020.110356
10. Souza Monteiro de Araujo D, Nassini R, Geppetti P, De Logu F. TRPA1 as a therapeutic target for nociceptive pain. Expert Opin Ther Targets 2020; 24: 997–1008. DOI: 10.1080/14728222.2020.1815191

11. Shi Y, Yuan S, Tang SJ. Reactive oxygen species (ROS) are critical for morphine exacerbation of HIV-1 gp120-induced pain. J Neuroimmune Pharmacol 2021; 16: 581–591. DOI: 10.1007/s11481-020-09951-6

12. Li PA, Hou X, Hao S. Mitochondrial biogenesis in neurodegeneration. J Neurosci Res 2017; 95: 2025–2029. DOI: 10.1002/jnr.24042

13. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem 2010; 47: 69–84. DOI: 10.1042/bse0470069

14. Sun J, Song FH, Wu JY, Zhang LQ, Li DY, Gao SJ, Liu DQ, Zhou YQ, Mei W. Sestrin2 overexpression attenuates osteoarthritis pain via induction of mitochondrial biogenesis and suppression of neuroinflammation. Brain Behavior, Immunity 2022; 102: 53–70. DOI: 10.1016/j.bbi.2022.02.015

15. Zhang LQ, Zhou YQ, Li JY, Sun J, Zhang S, Wu JY, Gao SJ, Tian XB, Mei W. 5-HT1F receptor agonist ameliorates mechanical allodynia in neuropathic pain via induction of mitochondrial biogenesis and suppression of neuroinflammation. Front Pharmacology 2022; 13: 834570. DOI: 10.3389/fphar.2022.834570

16. Chen N, Ge MM, Li DY, Wang XM, Liu DQ, Ye DW, Tian YK, Zhou YQ, Chen JP. beta2-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis. Biomed Pharmacotherapy 2021; 144: 112331. DOI: 10.1016/j.biopharma.2021.112331

17. Catanzaro E, Calcabroni C, Turrini E, Sestili P, Fimognari C. Nrf2: a potential therapeutic target for naturally occurring anticancer drugs? Expert Opin Ther Targets 2017; 21: 781–793. DOI: 10.1080/14728222.2017.1351549

18. Silva-Islas CA, Maldonado PD. Canonical and non-canonical mechanisms of Nrf2 activation. Pharmacol Res 2018; 134: 92–99. DOI: 10.1016/j.phrs.2018.06.013

19. Zhou YQ, Mei W, Tian XB, Tian YK, Liu DQ, Ye DW. The therapeutic potential of Nrf2 inducers in chronic pain: evidence from preclinical studies. Pharmacol Therapeutics 2021; 225: 107846. DOI: 10.1016/j.pharmthera.2021.107846

20. Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kessler TW, Dinkova-Kostova AT. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 2019; 18: 295–317. DOI: 10.1038/s41573-018-0008-x

21. Dinkova-Kostova AT, Abramov AY. The emerging role of Nrf2 in mitochondrial function. Free Radical Biol Med 2015; 88: 179–188. DOI: 10.1016/j.freeradbiomed.2015.04.036

22. Sun J, Li JY, Zhang LQ, Li DY, Wu JY, Gao SJ, Liu DQ, Zhou YQ, Mei W. Nrf2 activation attenuates chronic constriction injury-induced neuropathic pain via induction of PGC-1alpha-mediated mitochondrial biogenesis in the spinal cord. Oxid Med Cell Longev 2021; 2021: 9577874. DOI: 10.1155/2021/9577874

23. Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev 2015; (4): CD011076. doi:10.1002/14651858.CD011076.pub2.

24. Liu L, Vollmer MK, Kelly MG, Fernandez VM, Fernandez TG, Kim H, Dore S. Reactive gliosis contributes to nrf2-dependent neuroprotection by pretreatment with dimethyl fumarate or korean red ginseng against hypoxic-ischemia: focus on hippocampal injury. Mol Neurobiology 2020; 57: 105–117. DOI: 10.1007/s12035-019-01760-0

25. Campolo M, Casili G, Biundo F, Crupi R, Cordaro M, Cuzzocrea S, Esposito E. The neuroprotective effect of dimethyl fumarate in an mptp-mouse model of parkinson’s disease: involvement of reactive oxygen species/nuclear factor-kappab/nuclear transcription factor related to NF-E2. Antioxid Redox Signal 2017; 27: 453–471. DOI: 10.1089/ars.2016.6800

26. Casili G, Lanza M, Filippone A, Campolo M, Paternini I, Cuzzocrea S, Esposito E. Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice. J Neuroinflammation 2020; 17: 59. DOI: 10.1186/s12974-020-01736-1

27. Li J, Ma J, Lacagnina MJ, Lorca S, Odem MA, Walters ET, Kavelaars A, Grace PM. Oral dimethyl fumarate reduces peripheral neuropathic pain in rodents via NFE2L2 antioxidant signaling. Anesthesiology 2020; 132: 343–356. DOI: 10.1097/ALN.0000000000003077

28. Hayashi G, Jasoliya M, Sahdeo S, Sacca F, Pane C, Fillia A, Marsili A, Puorro G, Lanzillo R, Brescia Morra V, Cortopassi G. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. Hum Mol Genet 2017; 26: 2864–2873. DOI: 10.1093/hmg/ddx167

29. Hui CK, Dedkova EN, Montgomery C, Cortopassi G. Dimethyl fumarate dose-dependently increases mitochondrial gene expression and function in muscle and brain of Friedrich’s ataxia model mice. Hum Mol Genet 2021; 29: 3954–3965. DOI: 10.1093/hmg/dda282

30. Zhou YQ, Liu DQ, Chen SP, Chen N, Sun J, Wang XM, Cao F, Tian YK, Ye DW. Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain. Acta Pharmacol Sin 2020; 41: 1041–1048. DOI: 10.1038/s41401-020-0394-6

31. Sagar DR, Burston JJ, Hathway GJ, Woodhams SG, Pearson RG, Bennett AJ, Kendall DA, Scammell BE, Chapman V. The contribution of spinal glial cells to chronic pain behaviour in the monosodium iodoacetate model of osteoarthritic pain. Mol Pain 2011; 7: 88. DOI: 10.1186/1744-8069-7-88

32. Sagar DR, Staniszewski LE, Okine BN, Woodhams S, Norris LM, Pearson RG, Garle MJ, Alexander SP, Bennett AJ, Barrett DA, Kendall DA, Scammell BE, Chapman V. Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor co-therapy in painful osteoarthritis: a systematic review and meta-
34. Sorge RE, Mapplebeck JC, Rosen S, Beggs S, Taves S, Alexander JK, Martin LJ, Austin JS, Sotocinal SG, Chen D, Yang M, Shi XQ, Huang H, Pillon NJ, Bilan P, Tu Y, Klip A, Ji RR, Zhang J, Salter MW, Mogil JS. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. *Nat Neurosci* 2015; 18: 1081–1083. DOI:10.1038/nn.4053

35. North RY, Li Y, Ray P, Rhines LD, Tatsui CE, Tao G, Johansson CA, Zhang H, Kim YH, Zhang B, Dussor G, Kim TH, Price TJ, Dougherty PM. Electrophysiological and transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. *Brain* 2019; 142: 1215–1226. DOI: 10.1093/brain/awz063

36. Xu BY, Sun J, Chen SP, Wang XM, Chen N, Li DY, Chen G, Mei W, Tian YK, Zhou YQ, Ye DW. Nox2 contributes to reactive oxygen species-induced redox imbalance in cancer-induced bone pain. *Am J Translational Research* 2021; 13: 1269–1279.

37. Martin-Montanez E, Pavia J, Valverde N, Boraldi F, Lara E, Oliver B, Hurtado-Guerrero I, Fernandez O, Garcia-Fernandez M. The S1P mimetic fingolimod phosphate regulates mitochondrial oxidative stress in neuronal cells. *Free Radic Biol Med* 2019; 137: 116–130. DOI: 10.1016/j.freeradbiomed.2019.04.022

38. Kudryavtseva AV, Krasnov GS, Dmitriev AA, Alekseev BY, Kardymon OL, Sadritdinova AF, Fedorova MS, Pokrovsy AV, Melnikova NV, Kaprin AD, Moskalety AA, Sneathkina AV. Mitochondrial dysfunction and oxidative stress in aging and cancer. *Oncotarget* 2016; 7: 44879–44905. DOI: 10.18632/oncotarget.9821

39. Sun H, Guo X, Wang Z, Wang P, Zhang Z, Dong J, Zhuang R, Zhou Y, Ma G, Cai W. Alphalipoic acid prevents oxidative stress and peripheral neuropathy in nab-paclitaxel-treated rats through the Nrf2 signalling pathway. *Oxid Med Cell Longev* 2019; 2019: 3142732. DOI: 10.1155/2019/3142732

40. Miao H, Xu J, Xu D, Ma X, Zhao X, Liu L. Nociceptive behavior induced by chemotherapeutic paclitaxel and beneficial role of antioxidative pathways. *Physiol Res* 2019; 68: 491–500. DOI: 10.33549/physiolres.933939

41. Dubrall D, Pflock R, Kosinska J, Schmid M, Bleich M, Himmerkus N, Offermans S, Schwaninger M, Sachs B. Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA2-mediated adverse reactions? A combined epidemiological-experimental approach. *Br J Clin Pharmacol* 2021; 87: 3813–3824. DOI: 10.1111/bcp.14787